Abstract Body

Background: HIV infection has been associated with increased risk of osteopenia/osteoporosis and fragility fractures. DXA is the reference standard to assess bone mass density (BMD), however it is a radiation-based and expensive technique, not easily accessible in several clinical settings. Quantitative ultrasound (QUS) of the heel is a radiation-free, easy-to-perform technique, which may help reducing the need for DXA scan.

Methods: In this cross-sectional study, we evaluated the prevalence of and risk factors for low BMD by QUS (Hologic Sahara) in a cohort of HIV-infected patients. We assessed the correlation between BMD and demographic, viro-immunological and biochemical parameters. Osteopenia/osteoporosis rates were compared with those of 36 sex- and age-matched HIV-negative controls. Mann-Whitney test was used to compare continuous variables, Chi-squared test for categorical variables. Spearman’s correlation and multivariate analysis were used to assess factors associated with low BMD.

Results: 152 HIV-positive patients were enrolled, 29% female, median age 47(IQR 39-54) years. 19% of patients were HCV-positive, 60% smokers, 7% had diabetes. Median BMI was 24(IQR 22-26) kg/m2. Median time since HIV diagnosis was 122(IQR 47-216) months, median time from HAART initiation 119(IQR 39-204) months. 91% were on HAART, 53% were receiving a PI-based regimen, 44% a NNRTI-based one, 11% were taking RAL, 60% TDF, 80% had undetectable viral load, median CD4 count was 548 (IQR 407-695) cells/μl.
The number of subjects with Sahara t-score <-1 was significantly higher among HIV-positive patients in comparison with controls (64 vs. 33%, p=0.012). 55% of HIV-positive patients had Sahara t-score <-1, 9% <-2.5). In the univariate but not in the multivariate analysis, factors associated with lower BMD were older age (p=0.002), lower CD4 at diagnosis (r=0.35, p=0.003), duration of tenofovir exposure (r=-0.19, p=0.02) and HCV coinfection (p=0.01).
According to guidelines, 41% of patients had risk factors for osteoporosis who make them eligible for DXA. By using QUS, we may avoid/delay DXA in around 30% of them. On the other hand, 59% of patients ineligible for DXA according to US HIV guidelines, had a low QUS t-score.

Conclusions: In our cohort, low BMD was highly prevalent. Heel QUS is a quick, easy-to-perform, relatively inexpensive and radiation-free technique which may help reducing the need for unnecessary DXA as well as identifying high-risk subjects, requiring a thorough workup.